CoChat

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA ‐ T2D trial

Open access
Groop, Per‐Henrik, Cooper, Mark E., Perkovic, Vlado, Hocher, Berthold, Kanasaki, Keizo, Haneda, Masakazu, Schernthaner, Guntram, Sharma, Kumar, Stanton, Robert C., Toto, Robert, Cescutti, Jessica, Gordat, Maud, Meinicke, Thomas, Koitka‐Weber, Audrey, Thiemann, Sandra, von Eynatten, Maximilian · 2017 · Diabetes, Obesity and Metabolism
Cited by 149

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aims: The MARLINA ‐ T2D study ( ClinicalTrials.gov , NCT 01792518) was designed to investigate the glycaemic and renal effects of linagliptin added to standard‐of‐care in individuals with type 2 diabetes and albuminuria. Methods: A total of 360 individuals with type 2 diabetes, HbA1c 6.5% to 10.0% (48–86 mmol/mol), estimated glomerular filtration rate ( eGFR ) ≥30 mL/min/1.73 m 2 and urinary albumin‐to‐creatinine ratio ( UACR ) 30–3000 mg/g despite single agent renin‐angiotensin‐system blockade were randomized to double‐blind linagliptin ( n = 182) or placebo ( n = 178) for 24 weeks. The primary and key secondary endpoints were change from baseline in HbA1c at week 24 and time‐weighted average of percentage change from baseline in UACR over 24 weeks, respectively. Results: Baseline mean HbA1c and geometric mean ( gMean ) UACR were 7.8% ± 0.9% (62.2 ± 9.6 mmol/mol) and 126 mg/g, respectively; 73.7% and 20.3% of participants had microalbuminuria or macroalbuminuria, respectively. After 24 weeks, the placebo‐adjusted mean change in HbA1c from baseline was −0.60% (−6.6 mmol/mol) (95% confidence interval [ CI ], −0.78 to −0.43 [−8.5 to −4.7 mmol/mol]; P < .0001). The placebo‐adjusted gMean for time‐weighted average of percentage change in UACR from baseline was −6.0% (95% CI , −15.0 to 3.0; P = .1954). The adverse‐event profile, including renal safety and change in eGFR , was similar between the linagliptin and placebo groups. Conclusions: In individuals at early stages of diabetic kidney disease, linagliptin significantly improved glycaemic control but did not significantly lower albuminuria. There was no significant change in placebo‐adjusted eGFR . Detection of clinically relevant renal effects of linagliptin may require longer treatment, as its main experimental effects in animal studies have been to reduce interstitial fibrosis rather than alter glomerular haemodynamics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13041

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 31

  1. 10.1016/j.clinthera.2009.10.020 · DOI
  2. 10.1111/j.1523-1755.2004.00653.x · DOI · Paper page
  3. 10.1681/ASN.2006050445 · DOI · Paper page
  4. 10.1161/01.CIR.0000139860.33974.28 · DOI · Paper page
  5. 10.1093/eurheartj/ehr017 · DOI · Paper page
  6. 10.1038/ki.2010.536 · DOI · Paper page
  7. American Diabetes Association, 2016, Standards of medical care in diabetes – 2016, Diabetes Care, 39, S1
  8. 10.1016/S2213-8587(16)30045-6 · DOI
  9. 10.1016/S0167-0115(99)00089-0 · DOI · Paper page
  10. 10.2337/db13-1029 · DOI · Paper page
  11. 10.1038/ki.2015.103 · DOI
  12. 10.1371/journal.pone.0141143 · doi:10.1371/journal.pone.0141143
  13. 10.1016/j.kint.2016.01.016 · DOI
  14. 10.2337/dc13-0323 · DOI · Paper page
  15. 10.1177/1479164115579002 · DOI
  16. Cooper ME, 2016, Haemodynamic effects of combination therapy with the DPP‐4 inhibitor linagliptin and renin‐angiotensin system inhibitors in patients with type 2 diabetes, Diabetologia, 56, S366
  17. 10.2337/dc12-0706 · DOI · Paper page
  18. 10.2337/dc14-1684 · DOI
  19. 10.1016/j.regpep.2006.12.016 · DOI · Paper page
  20. 10.1097/HJH.0000000000000328 · DOI
  21. 10.1016/S0065-1281(11)80302-8 · doi:10.1016/s0065-1281(11)80302-8
  22. 10.1007/s00125-016-4008-2 · DOI · Paper page
  23. 10.1111/dom.12654 · DOI · Paper page
  24. 10.1007/s00125-008-0961-8 · DOI · Paper page
  25. 10.1210/jc.2015-3716 · DOI
  26. 10.2337/db16-0317 · DOI · Paper page
  27. 10.1016/j.kint.2016.06.012 · DOI
  28. 10.1097/HJH.0b013e3283649b4d · DOI
  29. 10.1186/1475-2840-12-125 · DOI · Paper page
  30. 10.1002/oby.20833 · DOI · Paper page
  31. 10.2337/dc16-0621 · DOI · Paper page

Cited by

See all 149

Metadata

Authors
Groop, P., Cooper, M. E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M., Schernthaner, G., Sharma, K., Stanton, R. C., Toto, R., Cescutti, J., Gordat, M., Meinicke, T., Koitka‐Weber, A., Thiemann, S., & von Eynatten, M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-07-31
Volume
19
Issue
11
Pages
1610-1619
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2639738157
Cited by
149
References
12
FWCI
13.55
Type
journal article
Language
en
Open access
hybrid
Funders
Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA ‐ T2D trial. https://app.cochat.ai/papers/10.1111/dom.13041
The paper
Groop, P., Cooper, M. E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M., Schernthaner, G., Sharma, K., Stanton, R. C., Toto, R., Cescutti, J., Gordat, M., Meinicke, T., Koitka‐Weber, A., Thiemann, S., & von Eynatten, M. (2017). Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA ‐ T2D trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.